Changes in Beneficial Ownership · 4
Entera Bio Ltd.
ENTXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
zk2635791.xml
Filing details
- Report period
- 2026-08-07
- Issuer
- Entera Bio Ltd.
- Issuer CIK
- 0001638097
- Trading symbol
- ENTX
Reporting owner 1
- Name
- Germano Geno J
- Reporting owner CIK
- 0001424383
- Relationship
- Director
- Address
- KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL, L3, 9112002
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value NIS 0.0000769 per share | 2026-08-07 | A · Form 4[F1] | 25,014 | A | 0 | 65,014 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 1.37 | 2026-08-07 | A · Form 4 | 50,000 | A | 0 | [F2] | 2036-05-07 | Ordinary Shares, par value NIS 0.0000769 per share | 50,000 | 50,000 | D |
| Stock Option (right to buy) | 1.37 | 2026-08-07 | A · Form 4 | 43,014 | A | 0 | [F3] | 2036-05-07 | Ordinary Shares, par value NIS 0.0000769 per share | 43,014 | 43,014 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.↩ 1
- F2
- Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).↩ 1
- F3
- Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).↩ 1
Signature 1
- Signed
- /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
- Date
- 2026-08-07